Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06613360 · ClinicalTrials.gov registry record · Phase 1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
A Phase 1 study of SLE and SLE (Systemic Lupus), sponsored by Cullinan Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 15
- Study locations
NCT06613360 is a Phase 1 study of SLE and SLE (Systemic Lupus) that is actively recruiting participants, run by Cullinan Therapeutics. The registered enrollment target is 24 participants, below the 87-participant average among 9 other SLE trials with a reported enrollment target (72% lower). The trial reports 15 study locations across 9 states.
The verdict
NCT06613360, a Phase 1 study of SLE and SLE (Systemic Lupus), is actively recruiting participants, sponsored by Cullinan Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 15
- Study locations
Study Summary
Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).
Conditions Studied
Interventions
- DRUG CLN-978
Study Locations (15)
Other
- Cullinan Investigative Site - Victoria Park
- Arensia Research Clinic - Sofia
- Arensia Research Clinic - Tbilisi
- Arensia Research Clinic - Chisinau
Arizona
- Cullinan Investigative Site - Avondale
- Cullinan Investigative Site - Tucson
New York
- Cullinan Investigative Site - New York
- Cullinan Investigative Site - Rochester
Texas
- Cullinan Investigative Site - Plano
- Cullinan Investigative Site - Webster
Florida
- Cullinan Investigative Site - Orlando
Iowa
- Cullinan Investigative Site - Iowa City
Tennessee
- Cullinan Investigative Site - Memphis
Utah
- Cullinan Investigative Site - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-01-21 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06613360
The ClinicalTrials.gov registry entry for NCT06613360 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 9 other SLE trials with a reported enrollment target (72% lower). The listed sponsor is Cullinan Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with SLE appearing as the primary indexed condition, and to 1 intervention - of which CLN-978 is the first listed.
NCT06613360 reports 15 study locations spanning 9 distinct geographic areas - top geographies include Other, Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT06613360 about?
NCT06613360 is a clinical study titled "A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus". Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).
What is the current status of trial NCT06613360?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-01-21. Estimated completion is 2027-12.
What conditions does trial NCT06613360 study?
This clinical trial studies the following conditions: SLE, SLE (Systemic Lupus).
What interventions are being tested in trial NCT06613360?
The interventions under investigation include: CLN-978 (DRUG).
Who is sponsoring clinical trial NCT06613360?
This trial is sponsored by Cullinan Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06613360 being conducted?
This trial has 15 study locations across Arizona, Florida, Iowa, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SLE
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
RECRUITING · Phase 1
-
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
RECRUITING · Phase 1
-
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy of ONT01 in Lupus
RECRUITING · Early Phase 1
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.